Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Ractigen Reveals Preclinical Results of RNA Therapy for Duchenne Muscular Dystrophy

publication date: Nov 3, 2023

Ractigen Therapeutics, a Jiangsu RNA activation (RNAa) company, presented preclinical results of its short duplex RNA (saRNA) technology to develop a gene therapy for Duchenne muscular dystrophy (DMD). The saRNA targets activation of utrophin to increase transcription of endogenous genes, leading to restoration of their protein function. The company says saRNA offers the possibility of modulating traditionally undruggable targets, one of the few technologies that can treat diseases by stimulating the expression of therapeutic genes with insufficient expression. More details....

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital